Top Markets
#1 PulseChain PulseChain +45.01%
#2 RedStone RedStone +16.75%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.64%
#4 Meteora Meteora +9.03%
#5 SkyAI SkyAI +8.73%
#6 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +8.09%
#7 Unit Pump Unit Pump +7.79%
#8 Pump.fun Pump.fun +7.79%
#9 Lighter Lighter +7.66%
#10 Lista DAO Lista DAO +7.22%
Coin of the day
PulseChain PulseChain
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Classement en actions #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Prix de l'action
$1.00
Dernière synchronisation: 2023-06-01
Capitalisation boursière
$30.11M
Changement (1 jour)
2.04%
Changement (1 an)
0.00%
Pays
US
Échange Angion Biomedica Corp. (ANGN)

Catégorie

Healthcare
Bénéfices pour Angion Biomedica Corp. (ANGN)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Angion Biomedica Corp., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Angion Biomedica Corp. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH